Black Diamond Therapeutics Inc (BDTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Black Diamond Therapeutics Inc (BDTX) has a cash flow conversion efficiency ratio of -0.074x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.14 Million) by net assets ($96.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Black Diamond Therapeutics Inc for the company's overall valuation and market capitalisation.
Black Diamond Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Black Diamond Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Black Diamond Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Black Diamond Therapeutics Inc ranked by their cash flow conversion efficiency. Explore Black Diamond Therapeutics Inc (BDTX) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
QRF SCA
BR:QRF
|
-0.001x |
|
Englewood Lab Inc
KQ:950140
|
0.044x |
|
Tera Autotech
TWO:6234
|
0.013x |
|
China Silver Group Limited
F:2CS
|
0.015x |
|
Payton -L
TA:PAYT
|
0.010x |
|
Affluent Medical SAS
PA:AFME
|
-0.319x |
|
Wielton S.A.
WAR:WLT
|
-0.086x |
|
Bright Sheland International Co Ltd
TWO:4556
|
0.038x |
Annual Cash Flow Conversion Efficiency for Black Diamond Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Black Diamond Therapeutics Inc from 2017 to 2025. View BDTX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $112.21 Million | $29.61 Million | 0.264x | +135.28% |
| 2024-12-31 | $83.28 Million | $-62.30 Million | -0.748x | -30.89% |
| 2023-12-31 | $116.74 Million | $-66.72 Million | -0.572x | +22.28% |
| 2022-12-31 | $115.69 Million | $-85.08 Million | -0.735x | -43.85% |
| 2021-12-31 | $195.90 Million | $-100.15 Million | -0.511x | -201.71% |
| 2020-12-31 | $307.76 Million | $-52.15 Million | -0.169x | -132.38% |
| 2019-12-31 | $-47.16 Million | $-24.67 Million | 0.523x | -3.81% |
| 2018-12-31 | $-15.54 Million | $-8.45 Million | 0.544x | +54.44% |
| 2017-12-31 | $-6.67 Million | $-2.35 Million | 0.352x | -- |
About Black Diamond Therapeutics Inc
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutan… Read more